FDA Floats Eliminating Multi-Ingredient Pediatric Cold Products
This article was originally published in The Pink Sheet Daily
Executive Summary
Consumer Healthcare Products Association, FDA agree labeling for OTC cough/cold drugs should indicate use is not safe for children under 2 years old, while Center for Drug Evaluation and Research cites “heightened risk of overdose due to concurrent therapy with multi-ingredient” products.
You may also be interested in...
Congress Likely To Legislate Monetary Penalty Authority In FTC Enforcement If SCOTUS Strikes It
White House, Democrat majority in Congress and likely next FTC chair support the agency wielding the authority, says advertising law attorney Holly Melton. Supreme Court, though, likely will rule in pending cases that a strict reading of an FTC regulation doesn’t grant monetary penalty authority.
Despite ‘Almost Nonexistent’ Cough/Cold Season, Perrigo's 2020 Consumer Health Sales Grow 6%
Perrigo is latest consumer health firm to note substantially slower flu rates slammed OTC drug sales during 2020 fourth quarter. Its total cough/cold product sales for the year were off $63m on decreases of $34m in the Americas and $29m in its international markets.
Subtracting Rx Adds To Perrigo OTC Pipeline
In deal with Altaris Capital, “I don't feel like we got out at any cost,” says Perrigo CEO Murray Kessler. Agreement calls for “a number of mutual long-term relationship components ... including on Rx-to-OTC switches."
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: